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“Molecular approaches will continue by ingenious innovations to make inroads in neuroscience at the
interface of physiology, cell biology and genetics. By its versatile nature, molecular biology ensures its
contribution to our understanding of the workings of the brain. This is the good news! The bad news is
that we need to wait to find out how.” (Seeburg, 2008).
On 22nd August 2016, the fields of molecular neurobiology and endocrinology lost one of
their pioneers and true giants, Peter Seeburg, who died aged 72, a day after his birthday. His
funeral ceremony took place in Heidelberg where he had worked since 1988, first as a professor
at the University of Heidelberg (ZMBH) and then since 1996 as a director of the Max Plank
Institute (Department of Molecular Neurobiology). Many of Peter’s former colleagues, students
and postdocs came together with his family members to celebrate his life. Touching eulogies were
given by no less than two Nobel prize winners: the physiologist Bert Sakmann, who collaborated
with Peter for many years, and the developmental biologist Christiane Nüsslein-Vollhard, who was
a friend and fellow PhD student with Peter. His professional contemporary, Heinrich Betz, gave
a warm and endearing assessment of Peter’s contributions to the field of molecular neurobiology.
One of Peter’s sons, Daniel P. Seeburg, now a neuroradiologist in the USA, and biotechnologist
Karoly Nikolics, one of Peter’s friends from the days of Genentech, both emotionally summed up
the warm and intense character of the man that many of his former students and postdocs knew.
SEEBURG CAREER OVERVIEW
Peter Seeburg pioneered the cloning and expression of recombinant hormones in E. coli for human
use. Beforehand, doctors had had to use hormones and peptides purified from animals, sometimes
with concurrent health risks for patients because of co-purified viruses or neurodegenerative
agents. This recombinant expression work was transformative for biotechnology. In particular, in
1979, Peter developed the expression of recombinant growth hormone, which is still sold today
(Goeddel et al., 1979). He and his colleagues made many contributions to the cloning of hormones
and their receptors, and he was streets ahead of many of his contemporaries in applying cloning
techniques to reveal the sequences of peptides, hormones, receptors and their gene structures. He
also developed several seminal molecular biology methods, such as shotgun sequencing (Messing
et al., 1981), later used in the genome sequencing programs. And so Peter, as one of the first
biotechnologists and members of Genentech, was already well known in his early forties as a
“molecular endocrinologist.” But perhaps we, as neuroscientists, know him best as one of the
“godfathers” of molecular neurobiology. In the 1980s and 1990s, Peter was one of the first scientists
to apply molecular biology techniques to characterize neurotransmitter receptors. His work, and
that of the teams he assembled and inspired, brought us the molecular descriptions and functional
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characterization of nearly all the GABAA receptor subunits,
many of the ionotropic glutamate receptor subunits (AMPA,
kainate, NMDA) and their properties, as well as the discovery
and importance of RNA editing in the nervous system. Later
he and his collaborators manipulated the expression and
properties of these genes in mouse models, and extended
the analysis of these subunits in vivo. His work set the
foundations for much of the molecular biology of ligand-
gated channels that is taken for granted as textbook knowledge
today.
SEEBURG: CAREER FOUNDATIONS IN
THE HEINZ SCHALLER LAB
Peter Seeburg was born in August 1944 in Querfurt near
Halle/Salle, in what became Eastern Germany (DDR) after
World War II. At the end of the war his family came to the
west and to Munich where he grew up. Between 1964 and
1967, he studied Chemistry at the University of Munich, and
then from 1967 to 1972 studied Biochemistry at the University
of Tübingen in the south west of Germany. He then joined
the virologist Heinz Schaller’s lab at the Max Planck Institute
for Virus Research Tübingen as a PhD student. Peter’s thesis
work on viral promoters was published as several papers (e.g.,
Seeburg and Schaller, 1975). According to Nüsslein-Vollhard,
the lab was exciting for many young biochemistry students.
In the late 1960s, Schaller, who was one of the molecular
biology pioneers, was giving lectures on DNA replication—
an exotic topic back then—and that was probably why Peter
joined the group. This was all before the modern methods of
DNA sequencing and other molecular biology techniques were
developed. On her Nobel laureate webpage Nüsslein-Vollhard
wrote: “Although I was an experienced molecular biologist, I
got bored with my projects at the end of my thesis (1973).
The prospect of continuing the study of transcriptional control
via the structure of promoter regions meant developing new
methods for DNA sequencing. The field of recombinant DNA
technology was growing and a fellow student and good friend,
Peter Seeburg, argued strongly for it. I was skeptical, and at that
early time, like most other people in Tübingen, did not foresee
its powers.” But Peter did, and for him, that meant moving with
a scholarship from the German Research Foundation (DFG) to
Howard Goodman’s lab in the Department of Biochemistry and
Biophysics at the University of California, San Francisco (UCSF)
where Peter continued to develop studies on cloning. At this
time, Peter was the quintessential hippie, with rings and long
hair, playing guitar, at one time in a band. With his celebrated
sharp humor, he brought a consistent and characteristic intensity
and practical brilliance to his lab work: smoking cigarettes,
drinking coffee and pipetting simultaneously (with probably
some other stimulants as well). His vigor, ambition and sense
of humor were qualities that would inspire his future students
and postdocs. In the Goodman lab, Peter was one of the first
to use the new cloning techniques to get sequence information
of hormones such as growth hormone (e.g., Seeburg et al.,
1977).
THE GENENTECH ERA: SHOTGUN
SEQUENCING, GROWTH HORMONE AND
NEUROENDOCRINOLOGY
In 1978 Peter, then aged 34, joined the company Genentech
in San Francisco. Genentech was a new breed of company,
dedicated to turning the fruits of molecular biology into
commerce. Together with colleagues such as his German
contemporary Axel Ullrich, who pursued a parallel career to Peter
with Goodman and then at Genentech (Ullrich et al., 1977; Sures
et al., 1980), the late 1970s and 1980s were Peter’s time to help
pioneer biotechnology. During this period, Peter and colleagues
developed several key molecular biology techniques, and one
in particular, shotgun DNA sequencing, has been enduring
(Messing et al., 1981). Rather than move linearly through a DNA
sequence, building a new sequencing primer as each new part of
the sequence was discovered, the shotgun method enabled rapid
dideoxy-sequencing of randomly (hence “shotgunned”) cloned
overlapping DNA fragments in piece-meal order, using just one
sequencing primer. The computer could then be used to piece
the multiple overlapping sequences together. Thus, sequences of
cDNAs, such as those encoding the hormones that Peter’s group
were working on, could be efficiently assembled. The method was
widely adopted. It was also the natural strategy for the genome
sequencing efforts that came several decades later. Continuing his
work from the Goodman lab (Seeburg et al., 1978), Peter’s group
was one of the first to express a recombinant protein in E. coli,
a method which underpins the biotechnology industry today
(Goeddel et al., 1979, 1980). This protein was growth hormone.
This work is the foundation of Peter’s early scientific reputation
(Seeburg, 1986).
At Genentech, Peter cemented the high publication rate that
would become a hallmark. For example, 1982 at Genentech
was a typical “Seeburg year”: he helped provide the sequence
of the Met- and Leu-enkephalin precursor genes (Comb et al.,
1982); together with Richard Axel and colleagues he dissected
the promoter elements of the growth hormone gene (Robins
et al., 1982); he extended into the genetic causes of growth
defects by looking at human families with growth hormone
mutations (Phillips et al., 1982); and his group provided the
entire (!) sequence of a viral genome, bovine papilloma virus
type 1 (Chen et al., 1982). The underlying theme always
being the application of cutting edge and high-throughput
molecular biology techniques. He later developed an interest in
Gonadotropin Releasing Hormone (GnRH), a peptide absolutely
needed for reproduction. He worked on a spontaneous mutant
mouse which did not have a functional GnRH gene, causing
poorly developed gonads, and thus could not reproduce.
Sensationally for the time, he and his collaborators could rescue
the phenotype of this mouse by using a GnRH transgene placed
into the genome of the mutant mouse (Mason et al., 1986).
This transgene contained all the regulatory regions needed to
express GnRH in the correct regions of the hypothalamus, and
this expression restored the ability of the hypogonadal mouse to
reproduce—in other words, this was one of the first successful
attempts at gene therapy (Mason et al., 1986). He was to return
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to GnRH neurons over a decade later, when his group studied
genetically labeled GnRH neurons in the hypothalamus using
electrophysiology to profile the neurotransmitter receptors on
these neurons to see how they secrete GnRH rhythmically
(Spergel et al., 1999). Peter’s last major Genentech study climaxed
with the sequence of the luteal lutropin receptor, a large G-
protein coupled receptor protein required for reproduction
(McFarland et al., 1989).
THE MOLECULAR NEUROSCIENCE ERA:
“SEEBURG NEVER SLEEPS”
During his time at Genentech, through his work on hormones
released from the hypothalamus and pituitary, Peter had become
more widely interested in brain function. His interest was
further stimulated when he was approached at Genentech by
Eric Barnard, a British protein chemist and neurochemist. In
the mid 1980s, little was known about molecular neuroscience.
There were few sequences available of any large proteins
expressed in the brain. Shosaku Numa and colleagues at the
Department of Medical Chemistry at Kyoto University in Japan
had published the sequences of themuscle nicotinic acetylcholine
receptor and voltage-gated sodium channels and had set the
standard high, having collaborated with Bert Sakmann on the
electrophysiological properties of these recombinant receptors
and ion channels (Sakmann et al., 1985; Mishina et al., 1986).
Barnard, then based at Imperial College London, together with
Ricardo Miledi, had pioneered injecting brain mRNA into
Xenopus oocytes, which translated this into receptors that could
be assayed electrophysiologically on the membrane of the cell
(Sumikawa et al., 1981). Barnard’s group were purifying the
GABAA receptor from bovine brains. In this they were successful
(Sigel et al., 1983), but turned to Peter Seeburg for help with the
cloning of receptor cDNAs.We need to remember that they asked
Peter because at that time few had competence in this new area,
molecular biology and cloning. Eric Barnard wanted to proceed
quickly and effectively, since there was competition to clone
the receptor from several other labs. Peter would have seemed
the man to deliver—and he did. Peter Seeburg’s team obtained
sequences of peptide fragments from the affinity purified GABAA
receptor given to them by Barnard’s group, which enabled Peter’s
team to make degenerate DNA primers, and screen cDNA
libraries. The cDNA libraries required special care, because it was
important that they contained full-length reading frames for large
proteins, which was a rare thing at the time. The isolated GABAA
receptor α1 and β1 subunit mRNAs encoding the subunits were
injected into Xenopus oocytes to assay their functional properties
and pharmacology. The results became a full article in Nature
detailing the sequence and some functional properties of the
GABAA receptor α and β subunits (Schofield et al., 1987). The
article appeared back-to-back with one from Heinrich Betz’s
group giving the structure and sequence of the glycine receptor
(Grenningloh et al., 1987), and it was apparent that together
with the nicotinic acetylcholine receptor, these receptors formed
a molecular superfamily. But this was only the start. In fact, it
was the springboard for Peter’s next career phase. In the late
1980s, Peter together with some talented colleagues, relocated
to the ZMBH at the University of Heidelberg in Germany,
where he set up a new lab (titled the Department of Molecular
Neuroendocrinology) on the opposite side of the corridor from
Heinrich Betz’s group. The “endocrinology” part of the lab title
was to prove largely historical.
As Betz pointed out in his eulogy, Peter Seeburg shook up
the field of molecular neuroscience because of his intensity and
organizational skills. Based on his experience and work ethic at
an American biotech company, Genentech, he accelerated the
pace at which sequences, subunits and their properties were
determined. In particular, rather than assigning one postdoctoral
RA or PhD student to do the whole project, or at least large
amounts of it (as was perhaps the case in the Steve Heinemann
or Heinrich Betz labs), Peter appointed a team of experts to take
on different aspects of the project. Another unique feature of the
time was organizing the lab with technical support, so that one
technician ran the DNA sequencing, another looked after cell
culture, etc. Having such a team, perhaps more commonplace
now, was way ahead of the Zeitgeist then. “Seeburg never sleeps”
was apparently a quote on the doors of some rival labs at the
time. Each Seeburg paper was constructed as a team effort,
passed on down the line: constructing cDNA libraries with full-
length clones (the entire reading frame); screening the libraries
with degenerate primers, subcloning the cDNAs into eukaryotic
expression vectors, rapid DNA sequencing, transfection into
mammalian cells with Genentech-based expression vectors for
state-of-the-art patch-clamp electrophysiology, looking at the
expression patterns of the mRNAs with in situ hybridization,
site-directed mutagenesis to test functional properties of the
subunits using ligand-binding or patch-clamp methods. The
electrophysiology was a key part of the endeavor, and here of
course, Bert Sakmann’s input and collaboration was critical. The
Sakmann lab was initially in Göttingen, and then relocated to
Heidelberg—Sakmann says that he invited Peter to move to
Göttingen, but Peter did not want to move, and so Sakmann
moved to Heidelberg! In 1991, there was an amazing atmosphere
when Sakmann and Erwin Neher received the Nobel prize for
developing the patch-clamp technique, and there was a big party
between the Sakmann and Seeburg labs.
SEEBURG LAB LIFE AT ZMBH, AT THE
UNIVERSITY OF HEIDELBERG
Seeburg lab life at ZMBH, at the university of Heidelberg. One
of this manuscript’s editors (JCM) told me that he was an
undergraduate studying biology at that time at the University
of Heidelberg, and remembers being inspired by the ideas and
power Peter seeded and spread among the students at the
ZMBH. The whole molecular neuroscience enterprise was driven
by Peter’s energetic nature. He did not like to be beaten and
science was a race to be first. For the glutamate receptor field
especially, Peter was worried. The labs of Steve Heinemann
at the Salk Institute in La Jolla in California, and of the
formidable molecular neurobiologist Shigetada Nakanishi at the
Institute of Immunolgy at Kyoto University (Japan), who had
Frontiers in Molecular Neuroscience | www.frontiersin.org 3 November 2016 | Volume 9 | Article 133
Wisden A Tribute to Peter H Seeburg
previously competed with Peter on isolating peptide hormone
cDNA sequences, were working on isolating neurotransmitter
receptors. Nakanishi had invented expression cDNA cloning
of receptors using the Xenopus oocyte system, and so could
scoop Peter’s team at any moment. In fact, Michael Hollmann
and colleagues in Heinemann’s group were first to the finish
line, isolating by expression cloning, the first AMPA/kainate
receptor subunit, GluA1, thus founding the subfield of glutamate
receptor molecular biology (Hollmann et al., 1989). Nakanishi’s
group did indeed go on to identify the following year, also by
expression cloning, the first NMDA receptor subunit GluN1
(Moriyoshi et al., 1991) and the first metabotropic glutamate
receptor mGluR1 (Masu et al., 1991). So in 1990, given the
competitive climate, Seeburg lab meetings for the people in his
group working on glutamate receptors often took place at 9
a.m. Saturday mornings, which was a challenge because at that
time in Germany, the shops were only open in the mornings on
Saturdays. And on Sundays, Peter always arrived with cake for
the lab at around 3 p.m. You were expected to be there. And
if you were not, he would say on Monday, “I didn’t see you
yesterday, I thought you were interested in this project.” Many
people benefited from Peter’s fervor, including me, then a young
and disorganized postdoc. A typical Seeburg weekday in the early
1990s, would be similarly intense. He would arrive in the lab at
around 7 a.m. His first pleasure of the day was to open the X-
ray film cassettes that were exposing the sequencing gels, develop
the films, and read the gels over cigarettes and coffee into the
computer, so that by the time the person leading on the project
got into the lab, Peter was already ready to discuss the next stages
of the work with them.
At ZMBH, Peter shared his office—whose door opened
straight into the lab—with his chief postdoc and right-hand man
Rolf Sprengel (who went onto share at least 92 publications with
Peter). Peter ran an open door policy: anyone could go in with
ideas, or to discuss data, at pretty much any time. Peter would
often be observed from the vantage point of the lab through
the open door standing at the phone, looking out the window
smoking, and he was often heard talking to the editors of the
Nature and Science journals. Alternatively, he might be seen
reading or writing, or looking at X-ray films of sequencing gels on
the lightbox, a cigarette always burning. He could also come out
at any time into the lab, to ask detailed questions, to encourage,
and tomotivate.When the sequencing technician was on holiday,
Peter would take over the lab sequencing himself, together with
copious quantities of 35S, cigarette ash, coffee and acrylamide.
Weekdays, Peter would leave around 7 p.m., after a 12-h day,
sometimes collecting postdocs or students that were around
and take them to dinner. Manuscripts were shaped up as the
work progressed. Peter liked scientific writing and getting to the
heart of a good sentence and its precise meaning. An enjoyable
aspect of writing manuscripts with Peter was that phrases would
be worked up through multiple drafts until the right level of
precision was reached. He liked words and their meanings. His
writing skill was consummate. With a word like “consummate,”
for example, he would ponder it, underline it in red, light a
cigarette, say it multiple times, blow out smoke, and say “yes,
consummate, a good word.” Reading and languages remained a
passionate hobby. In addition to his perfect midatlantic English,
he enjoyed learning and speaking Russian, Italian and latterly
he apparently took up and read some works in Latin. He was
also fluent in the language of DNA, of all its codes and cryptic
sequences. In 1990, Peter decided that Hannah Monyer and I
needed to learn the genetic code off-by-heart. “GAA codes for
what amino acid?” he would ask us; or, “Tell me what ‘CCC’
codes for?” Every day, one of these questions. We always got
these wrong, which he found amusing and so decided that we
were hopeless cases for passing the “DNA fluency” test. But one
day I defeated him: “What does UGA mean?” I asked him. “Stop
codon of course” he replied. “No!—it can be selenocysteine!” I
quipped back with some satisfaction (I happened to have just
read randomly in Nature that it was a newly discovered tRNA—
Forchhammer et al., 1989), and so the master of molecular
biology had to concede that he had learnt one (rare) codon
from me!
Peter’s most prolific scientific period as a lab head in the
field of molecular neurobiology was probably during the late
1980s to mid 1990s, when he was in his mid to late forties
(see portrait in Figure 1). There were many key discoveries of
this early molecular neurobiology period at ZMBH for Peter
and his colleagues. It almost seemed like a Nature, Science, or
Neuron paper per month, or sometimes several. The intensity of
it was glorious. Some personal choices for GABAA receptors are:
cloning nearly the whole subunit family (e.g., Levitan et al., 1988;
Pritchett et al., 1989a; Shivers et al., 1989; Seeburg et al., 1990); the
use of mammalian cell lines (e.g., HEK293 cells) for expression of
receptor subunits, now a routine method for all labs in this area
(Pritchett et al., 1988); characterization of the benzodiazepine
pharmacology of GABAA receptors (Pritchett et al., 1989b;
Lüddens et al., 1990; Korpi et al., 1993); identification of the
R/H position in the GABAA receptor α subunits that determined
benzodiazepine sensitivity (Wieland et al., 1992), knowledge
which allowed the group of HannsMöhler in Zurich to do elegant
work constructing a series of α subunit knock-in mice to test how
benzodiazepines produce their selective effects such as sedation
FIGURE 1 | Peter Seeburg in the ZMBH years, taken in 1993.
Reproduced with permission from Universitätsarchiv Heidelberg. Photograph:
Michael Schwarz.
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or anxiolysis (Rudolph et al., 1999; Löw et al., 2000); andmapping
expression of GABAA receptor gene family expression patterns
(Wisden et al., 1992).
Some personal choices for Peter’s impact on glutamate
receptors are: AMPA, kainate and NMDA receptor gene
heterogeneity (Keinänen et al., 1990; Werner et al., 1991; Herb
et al., 1992; Monyer et al., 1992, 1994); the discovery of flip
and flop splicing isoforms of AMPA receptor subunits and
their functional significance (Sommer et al., 1990; Mosbacher
et al., 1994); the discovery of selective Ca2+ permeability of
some AMPA receptor subunit combinations (Verdoorn et al.,
1991; Burnashev et al., 1992a); the probing of NMDA receptor
channel structure to reveal the importance of a critical asparagine
(Burnashev et al., 1992b; Kuner et al., 1996); the use of yeast
two-hybrid screening to discover PSD95 binding to the receptor
C-terminus of NMDA receptor subunits (Kornau et al., 1995);
and as a little side line, in a short reinvigoration of his
endocrinology days, the molecular description by expression
cloning of the pituitary adenylyl cyclase-activating polypeptide
(PACUP) receptor and its signaling (Spengler et al., 1993).
The crowning molecular biology glory, and in retrospect most
novel finding of all, was the discovery of RNA editing and its
molecular and enzymatic mechanisms, and this deserves some
extra mention. Bernd Sommer in Peter’s group discovered that
a critical nucleotide, adenosine, is changed to inosine in the
AMPA receptor GluR2 subunit nuclear transcripts by adenosine
deaminase enzymes (Sommer et al., 1991; Higuchi et al., 1993;
Melcher et al., 1996a). This A to I nucleotide transition, termed
editing, effects a change in the codon for glutamine (Q) to
arginine (R) in a critical transmembrane part of the GluR2
subunit and governs Ca2+ permeability (Burnashev et al., 1992a),
and also influences receptor kinetics (Lomeli et al., 1994). Peter’s
group showed that nearly 100% of GluR2 transcripts are edited,
and that when editing of GluR2 transcripts fails, which they
arranged to happen in transgenic mice, it has a lethal effect
because of the heightened Ca2+ entry into neurons (Brusa et al.,
1995; Feldmeyer et al., 1999; Rosenthal and Seeburg, 2012). Even
today, that 100% editing of the GluR2 gene takes place seems a
mysterious phenomenon. Why not just have the critical codon
in the GluR2 gene set to encode R in the first place rather than
go through the process of editing? We still do not know why the
process evolved. Perhaps RNA editing represents a snapshot of an
evolutionary transition to the genome. Peter’s group also found
that transcripts encoding the kainate receptor subunits were also
partially edited and this influenced the calcium permeability of
the various subunit combinations (Köhler et al., 1993). In fact,
many targets for RNA editing beyond those transcripts encoding
ionotropic glutamate receptors were subsequently discovered
by Peter’s group and others, and the editing process is overall
important for healthy physiological function (Hartner et al., 2004;
Horsch et al., 2011; Rosenthal and Seeburg, 2012).
THE MAX PLANK YEARS
The offer to Peter of a prestigious directorship to head up a
new Department of Molecular Neurobiology at the Max Planck
Institute for Medical Research in Heidelberg, in parallel with Bert
Sakmann’s Department in the same institute, was well deserved.
Around the same time Peter was also offered anMPI directorship
in Munich, but he declined. So he and his colleagues moved to
the Heidelberg MPI in 1996. At that time, he was around 52 years
old, and had already achieved an enormous scientific impact and
permanently cemented his reputation. The painstaking genetic
work that subsequently followed from this MPI period was
inevitably slower than perhaps the classical Seeburg style would
have preferred, and possibly his impatient temperament would
have been more suited to pursuing more proteomics-type studies
(see quote at start of article!). In later years Peter wrote the
following passage, which probably reflected his position at the
start of his MPI period: “A molecular neuroscientist with a
pessimistic bent might feel that his field is coming to a close,
seeing that most molecules contributing to a neuron’s well-being
and functional states are now known to us. There will still be
unexplored ion channels and transcription factors in our genome,
but isn’t it merely a matter of time before these will be dragged
onto the experimental stage? His colleague with an optimistic
outlook, exulting in the great possibilities that molecular tools put
at our disposal, will see himself more at the dawn of molecular
neuroscience. The realist takes his position somewhere between
these two extremes, realizing that he faces major challenges if he
desires to contribute meaningfully to neuroscience by continuing
to explore the molecular terrain” (Seeburg, 2008).
In the subsequent 20 years following 1996, Peter and his
colleagues Rolf Sprengel and Mia Higuchi used the freedom of
MPI funding to publish collectively well over another 120 (!)
papers, and expand further into manipulating the expression
of the receptor subunits in transgenic and knockout mice,
making knock-in point mutant mouse lines to reveal the
critical importance of amino acid residues or whole regions in
AMPA and NMDA receptor subunits (e.g., Sprengel et al., 1998;
Krestel et al., 2004), and elucidating further the enzymology
and sequence requirements of the brain RNA editing system,
and highlighting the importance of RNA editing in the brain
and other organs and tissues (Herb et al., 1996; Melcher et al.,
1996b; Köhr et al., 1998; Seeburg et al., 1998; Feldmeyer et al.,
1999; Higuchi et al., 2000; Hartner et al., 2004; Horsch et al.,
2011). The Seeburg and Sprengel teams also collaborated with
the mouse behavioral experts David Bannerman and Nick
Rawlins at the University of Oxford, exploring the importance
of hippocampal LTP for memory using, for example, mice
with the NMDA receptor GluN1 gene deleted from dentate
granule cells and CA1 pyramidal neurons (Bannerman et al.,
2012, 2014). They found that although these hippocampal
Grin1 knockout mice had no LTP onto pyramidal cells or
dentate granule cells they could still perform certain memory
tasks, challenging the presumption that the NMDA receptor is
essential for cognitive memory formation (Bannerman et al.,
2012, 2014). Peter also continued to collaborate with former
group member Hannah Monyer, who subsequently became his
deepest friend and “Lebensmench,” and who looked after and
cared for him during his long illness. Their last paper together,
with joint PhD student Frauke Leitner, concerned studying
the circuitry of olfactory processing in the entorhinal cortex
(Leitner et al., 2016).
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There was also some personal turbulence for Peter in the late
1990s with Genentech, with a legal dispute and trial centered
around the ownership of patents and receipt of profits over
recombinant growth hormone (Seeburg, 1999). Some colleagues,
newspapers and magazines misunderstood or condemned Peter’s
position, invoking the deliberate misidentification of a plasmid
for commercial reasons in a Nature paper. But not all was
bleak: Peter was supported publically by Nüsslein-Vollhard and
the science and its importance was never in dispute. As Peter
wrote in a correspondence to Nature: “As I emphasized during
the trial, all scientific results and conclusions of the Nature
paper (Goeddel et al., 1979) are unambiguous and correct. The
expression vector is exactly as described in the publication. The
study in the paper forms the basis for the first human growth
hormone preparation free of neurodegenerative agents, and the first
recombinant therapeutic to be marketed by Genentech, from which
100,000 children benefit worldwide” (Seeburg, 1999).
CODA
Finally, let us finish by ascendingMountOlympus: Peter’s metrics
are impressive. Even those who dispute the value of metrics
would have to concede that they do, in Peter’s case, accurately
describe the massive impact his body of work has had: an
h-index of 140; 16 papers cited over a thousand times each, 24
papers cited above 500 times each, and a career total of about
84,000 citations and at least 342 publications (Sources: Web of
Science and PubMed). He was elected an EMBO member in
1987. Peter garnered many prizes: the NEN Dupont Prize (1992),
the Ernst Shering prize (1992), the TiPS/TINS lecture at the
1992 European Neuroscience Association (Seeburg, 1993), the
Beckurts Prize (1992), the Feldberg prize (1993), a Bristol-Myers
Squibb Unrestricted Award in Neuroscience (1997–1999), the
1997 ECNP-Lilly award, and in 2007 the InBev-Baillet Latour
Health Prize. But Peter also gave to the community. He served
on the edtrorial boards of numerous journals and of course, had
contributed to the start, as its Chief Editor, of the Frontiers in
Molecular Neuroscience journal where this article is published.
Coming full circle, he served generously on the advisory board
of the Chica and Heinz Schaller Foundation, an organization set
up by his PhD supervisor, Heinz Schaller and Heinz’s wife the
developmental biologist Chica Schaller, to promote young career
scientists and initiatives in neuroscience and infectious diseases.
In the early 1990s in Heidelberg, American Armed Forces
radio was often on in the lab; when he heard a Jimi Hendrix
track, Peter would come out of his office, turn up the lab radio,
and play air guitar. The lab would stop and marvel. Hendrix
was his all-time favorite, Peter had a picture of Hendrix on his
office shelf, and for the postdocs and students in the lab, the rock
musician seemed to sum up the scientist. Peter’s metrics are a
series of Golden Number 1’s in the publication stakes. He had
so many hits. Peter was a strict boss, but also a loving and loyal
friend to some. He was often great fun and a shrewd observer.
He enjoyed dining out, and had many entertaining anecdotes
relating to science or personalities. He had a sharp wit and wicked
chuckle. He could be undoubtedly difficult, but also deeply warm
and generous. For the many students and postdocs in his group
over the years, as their supervisor and mentor, he inspired them
to achieve their best. Fittingly, his funeral service played out with
Voodoo Child.
In Memory of Peter H Seeburg (21st August 1944–22nd
August 2016) (Figure 1).
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